Molecular network analysis of signaling pathways in metastatic breast cancer in patients treated with erlotinib.

被引：0
|
作者：
Speer, R.
Wallwiener, D.
Yang, S. X.
Swain, S. M.
Wulfkuhle, J. D.
Liotta, L. A.
Petricoin, E. F.
机构：
[1] Univ Tubingen, Tubingen, Germany
[2] NCI, Bethesda, MD 20892 USA
[3] George Mason Univ, Manassas, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10064
引用
收藏
页码：556S / 556S
页数：1
相关论文
共 50 条
  • [31] Association of high circulating neuregulin-1 with clinical benefit in EGFR wildtype NSCLC patients treated with rilotumumab and erlotinib.
    Stabile, Laura P.
    Tarhini, Ahmad A.
    Farooqui, Mariya
    Gomez-Garcia, Jose
    Gaither-Davis, Autumn
    Gooding, William E.
    Socinski, Mark A.
    Siegfried, Jill M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
    Fasching, P. A.
    Brucker, S. Y.
    Fehm, T. N.
    Overkamp, F.
    Janni, W.
    Wallwiener, M.
    Hadji, P.
    Belleville, E.
    Haeberle, L.
    Taran, F. -A.
    Lueftner, D.
    Lux, M. P.
    Ettl, J.
    Mueller, V.
    Tesch, H.
    Wallwiener, D.
    Schneeweiss, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2015, 75 (01) : 41 - 50
  • [33] IMPACT OF MOLECULAR SUBTYPES IN PATIENTS WITH METASTATIC BREAST CANCER AT DIAGNOSIS
    Madureira, Tania
    Luz, Paulo
    Dias, David
    Dionisio, Raquel
    Gosalbez, Beatriz
    Furtado, Irene
    BREAST, 2017, 36 : S62 - S62
  • [34] Molecular Pathways: MERTK Signaling in Cancer
    Cummings, Christopher T.
    DeRyckere, Deborah
    Earp, H. Shelton
    Graham, Douglas K.
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5275 - 5280
  • [35] A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer.
    Blaszkowsky, LS
    Kulke, KH
    Ryan, DP
    Clark, JW
    Meyerhardt, J
    Zhu, AX
    Lawrence, C
    Fuchs, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 332S - 332S
  • [36] Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC).
    Meyerhardt, JA
    Xhu, A
    Enzinger, PC
    Ryan, DP
    Clark, JW
    Kulke, MH
    Michelini, A
    Vincitore, M
    Thomas, A
    Fuchs, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 265S - 265S
  • [37] Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy
    Perroud, Herman A.
    Alasino, Carlos M.
    Rico, Maria J.
    Queralt, Francisco
    Pezzotto, Stella M.
    Rozados, Viviana R.
    Scharovsky, O. Graciela
    FUTURE ONCOLOGY, 2016, 12 (10) : 1233 - 1242
  • [38] Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines
    Vassilomanolakis, M
    Koumakis, G
    Barbounis, V
    Demiri, M
    Pateras, H
    Efremidis, AP
    ANNALS OF ONCOLOGY, 2000, 11 (09) : 1155 - 1160
  • [39] Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
    Clayton, AJ
    Danson, S
    Jolly, S
    Ryder, WDJ
    Burt, PA
    Stewart, AL
    Wilkinson, PM
    Welch, RS
    Magee, B
    Wilson, G
    Howell, A
    Wardley, AM
    BRITISH JOURNAL OF CANCER, 2004, 91 (04) : 639 - 643
  • [40] Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
    A J Clayton
    S Danson
    S Jolly
    W D J Ryder
    P A Burt
    A L Stewart
    P M Wilkinson
    R S Welch
    B Magee
    G Wilson
    A Howell
    A M Wardley
    British Journal of Cancer, 2004, 91 : 639 - 643
12345